Li Zhou

6PUBLICATIONS
36CO-AUTHORS
Molecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|May 12, 2026
Adaptive Dosing Trial Simulation Framework to Inform Dose Optimization: Case Study Using Longitudinal PKPD Models With PF-06804103 Phase 1 Data in Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Positive and Low Solid Tumors.

|Apr 17, 2025
First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer.

Timothy A Yap, Jonathan W Goldman, Shaveta Vinayak

|Oct 26, 2023
Oncology Combination Dose-Finding Study Design for Targeted and Immuno-Oncology Therapies.

Li Zhou, Micaela B Reddy, Rajendar K Mittapalli

|Jul 07, 2023
Safety and Tolerability of a Novel Anti-HER2 Antibody-Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study.

Funda Meric-Bernstam, Emiliano Calvo, Keun Seok Lee

|Apr 03, 2020
A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2- Primary Breast Cancer.

John F R Robertson, Abigail Evans, Stephan Henschen

Pageof 1

Frequent Collaborators

2 joint publications

Stephan Henschen

2 joint publications

Cliona C Kirwan

2 joint publications

Peter A Fasching

2 joint publications

Kwok-Leung Cheung